Q3 2024 Dare Bioscience Inc Earnings Call Transcript

Nov 14, 2024 / 09:30 PM GMT

Release Date Price: $3.57 (-7.04%)

Transcript 8-K10-Q

Key Points

Positve

Dare Bioscience Inc (DARE) secured over $20 million in non-dilutive funding in the last 30 days, including a $10.7 million grant from the Bill and Melinda Gates Foundation.
The company has a broad portfolio focused on women's health, with ongoing advancements in contraception, sexual health, pelvic pain, fertility, infectious disease, and menopause.
Dare Bioscience Inc (DARE) is progressing with its first FDA-approved product, Clindamycin phosphate vaginal gel, for bacterial vaginosis, with increasing prescription rates.
The company is advancing its late-stage candidates, including Ovaprene, a hormone-free contraceptive, and Sildenafil Cream for female sexual arousal disorder, with ongoing FDA interactions.
Dare Bioscience Inc (DARE) has established a $15 million equity line arrangement with Lincoln Park Capital Fund LLC, enhancing its financial flexibility.

Negative

General and administrative expenses increased by 24% compared to Q3 2023, indicating higher operational costs.
The company's comprehensive loss for the third quarter was approximately $4.7 million, reflecting ongoing financial challenges.
R&D expenses decreased by 60% compared to Q3 2023, which may indicate reduced investment in research and development activities.
The company faces uncertainties related to FDA approval processes for its late-stage candidates, which could impact timelines and outcomes.
Dare Bioscience Inc (DARE) needs to secure additional funding to fully support its clinical trials, particularly for the Sildenafil Cream program.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

DARE.OQ - Dare Bioscience Inc
Q3 2024 Dare Bioscience Inc Earnings Call
Nov 14, 2024 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the conference call hosted by Dare Bioscience to review the company's third quarter financial results and to provide a general business update, this call is being recorded. My name is Desiree and I will be your operator today with us today from Dry are Sabrina Martucci Johnson, President and Chief Executive Officer and Marty Herring Leighton, Chief Accounting Officer, Miss Herring Laden. Please proceed.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon and welcome to the Dare bioscience, financial results and business update call for the quarter ended

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.